| Patent Number |
Title Of Patent |
Date Issued |
| 7335370 |
Chlamydia antigens and corresponding DNA fragments and uses thereof |
February 26, 2008 |
| The present invention provides a method of immunizing a host against disease caused by infection by a strain of Chlamydia, specifically C. pneumoniae. The method involves nucleic acid immunization, including DNA immunization, and employs a vector containing a nucleotide sequence which |
| 7326545 |
Chlamydia antigens and corresponding DNA fragments and uses thereof |
February 5, 2008 |
| The present invention provides a method of nucleic acid, including DNA, immunization of a host, including humans, against disease caused by infection by a strain of Chlamydia, specifically C. pneumoniae, employing a vector containing a nucleotide sequence encoding a 98 kDa outer memb |
| 7314869 |
Chlamydia antigens and corresponding DNA fragments and uses thereof |
January 1, 2008 |
| The present invention provides a method of nucleic acid, including DNA, immunization of a host, including humans, against disease caused by infection by a strain of Chlamydia, specifically C. pneumoniae, employing a vector containing a nucleotide sequence encoding OMP (outer membrane |
| 7297341 |
Chlamydia antigens and corresponding DNA fragments and uses thereof |
November 20, 2007 |
| The present invention provides purified and isolated polynucleotide molecules that encode Chlamydia polypeptides which can be used in methods to prevent, treat, and diagnose Chlamydia infection. In one form of the invention, the polynucleotide molecules are selected from DNA that encode |
| 7285276 |
Chlamydia antigens and corresponding DNA fragments and uses thereof |
October 23, 2007 |
| The present invention provides vaccines and methods for immunizing a host, including humans, against disease caused by infection by a strain of Chlamydia, specifically C. pneumoniae. The vaccine and method employ a 60 kDa cysteine-rich membrane protein of a strain of Chlamydia pneumoniae |
| 7183402 |
Chlamydia antigens and corresponding DNA fragments and uses thereof |
February 27, 2007 |
| The present invention provides a method of nucleic acid, including DNA, immunization of a host, including humans, against disease caused by infection by a strain of Chlamydia, specifically C. pneumoniae, employing a vector containing a nucleotide sequence encoding a 60 kDa cysteine-rich |
| 7166289 |
Nucleic acid molecules encoding inclusion membrane protein C of Chlamydia |
January 23, 2007 |
| The present invention provides a method of nucleic acid, including DNA, immunization of a host, including humans, against disease caused by infection by a strain of Chlamydia, specifically C. pneumoniae, employing a vector, containing a nucleotide sequence encoding an inclusion membrane |
| 7081245 |
Chlamydia antigens and corresponding DNA fragments and uses thereof |
July 25, 2006 |
| The present invention provides nucleic acids, proteins and vectors for a method of nucleic acid, including DNA, immunization of a host, including humans, against disease caused by infection by a strain of Chlamydia, specifically C. pneumoniae. The method employs a vector containing a |
| 7070792 |
Chlamydia antigens and corresponding DNA fragments and uses thereof |
July 4, 2006 |
| The present invention provides a method of nucleic acid, including DNA, immunization of a host, including humans, against disease caused by infection by a strain of Chlamydia, specifically C. pneumoniae, employing a vector containing a nucleotide sequence encoding full-length, 5'-tru |
| 7019125 |
Chlamydia antigens and corresponding DNA fragments and uses thereof |
March 28, 2006 |
| The present invention provides a method of nucleic acid, including DNA, immunization of a host, including humans, against disease caused by infection by a strain of Chlamydia, specifically C. pneumoniae, employing a vector containing a nucleotide sequence encoding an omp P6 precursor of |
| 6872814 |
Chlamydia antigens and corresponding DNA fragments and uses thereof |
March 29, 2005 |
| In summary of this disclosure, the present invention provides a method of nucleic acid, including DNA, immunization of a host, including humans, against disease caused by infection by a strain of Chlamydia, specifically C. pneumoniae, employing a vector, containing a nucleotide sequence |
| 6808713 |
Chlamydia antigens and corresponding DNA fragments and uses thereof |
October 26, 2004 |
| The present invention provides a method of immunizing a host against disease caused by infection by a strain of Chlamydia, specifically C. pneumoniae. The method involves nucleic acid immunization, including DNA immunization, and employs a vector containing a nucleotide sequence which |
| 6693087 |
Nucleic acid molecules encoding POMP91A protein of Chlamydia |
February 17, 2004 |
| An isolated and purified nucleic acid molecule encoding a POMP91A protein of a strain of Chlamydia, is useful for nucleic acid immunization of a host, including a human host, against disease caused by infection by a strain of Chlamydia, particularly C. pneumoniae. |
| 6686339 |
Nucleic acid molecules encoding inclusion membrane protein C of Chlamydia |
February 3, 2004 |
| In summary of this disclosure, the present invention provides a method of nucleic acid, including DNA, immunization of a host, including humans, against disease caused by infection by a strain of Chlamydia, specifically C. pneumoniae, employing a vector, containing a nucleotide sequence |
| 6660275 |
Chlamydia antigens and corresponding DNA fragments and uses thereof |
December 9, 2003 |
| The present invention provides a method of nucleic acid, including DNA, immunization of a host, including humans, against disease caused by infection by a strain of Chlamydia, specifically C. pneumoniae, employing a vector, containing a nucleotide sequence encoding a CPN100605 polype |
| 6649370 |
Chlamydia antigens and corresponding DNA fragments and uses thereof |
November 18, 2003 |
| In summary of this disclosure, the present invention provides a method of nucleic acid, including DNA, immunization of a host, including humans, against disease caused by infection by a strain of Chlamydia, specifically C. pneumoniae, employing a vector, containing a nucleotide sequence |
| 6642025 |
Chlamydia antigens and corresponding DNA fragments and uses thereof |
November 4, 2003 |
| In summary of this disclosure, the present invention provides a method of nucleic acid, including DNA, immunization of a host, including humans, against disease caused by infection by a strain of Chlamydia, specifically C. pneumoniae, employing a vector, containing a nucleotide sequence |
| 6607730 |
Chlamydia antigens and corresponding DNA fragments and uses thereof |
August 19, 2003 |
| In summary of this disclosure, the present invention provides a method of nucleic acid, including DNA, immunization of a host, including humans, against disease caused by infection by a strain of Chlamydia, specifically C. pneumoniae, employing a vector, containing a nucleotide sequence |
| 6521745 |
Nucleic acid molecules encoding inclusion membrane protein C of Chlamydia |
February 18, 2003 |
| An isolated and purified nucleic acid molecule encoding an inclusion membrane protein C of a strain of Chlamydia, is useful for nucleic acid immunization of a host, including a human host, against disease caused by infection by a strain of Chlamydia, particularly C. pneumoniae. |
| 6403102 |
Chlamydia antigens and corresponding DNA fragments and uses thereof |
June 11, 2002 |
| In summary of this disclosure, the present invention provides a method of nucleic acid, including DNA, immunization of a host, including humans, against disease caused by infection by a strain of Chlamydia, specifically C. pneumoniae, employing a vector, containing a nucleotide sequence |
| 6403101 |
Chlamydia antigens and corresponding DNA fragments and uses thereof |
June 11, 2002 |
| In summary of this disclosure, the present invention provides a method of nucleic acid, including DNA, immunization of a host, including humans, against disease caused by infection by a strain of Chlamydia, specifically C. pneumoniae, employing a vector, containing a nucleotide sequence |
| 6309649 |
Subunit respiratory syncytial virus vaccine preparation |
October 30, 2001 |
| The fusion (F) protein, attachment (G) protein and matrix (M) protein of respiratory syncytial virus (RSV) are isolated and purified from respiratory syncytial virus by mild detergent extraction of the proteins from concentrated virus, loading the protein onto a hydroxyapatite or oth |
| 6168928 |
Modification of pertussis toxin |
January 2, 2001 |
| The three-dimensional structure of crystalline pertussis holotoxin (PT) has been determined by X-ray crystallography. Crystal structures have also been determined for complexes of pertussis toxin with molecules relevant to the biological activity of PT. These three-dimensional structures |
| 6153580 |
Analog of haemophilus Hin47 with reduced protease activity |
November 28, 2000 |
| An isolated and purified analog of Haemophilus influenzae Hin47 protein has a decreased protease activity which is less than about 10% of that of natural Hin47 protein and preferably substantially the same immunogenic properties as natural Hin47 protein. An isolated an purified nucleic a |
| 6147057 |
Analog of Haemophilus Hin47 with reduced protease activity |
November 14, 2000 |
| An isolated and purified analog of Haemophilus influenzae Hin47 protein has a decreased protease activity which is less than about 10% of that of natural Hin47 protein and preferably substantially the same immunogenic properties as natural Hin47 protein. An isolated an purified nucleic a |
| 6114125 |
Analog of Haemophilus Hin47 with reduced protease activity |
September 5, 2000 |
| An isolated and purified analog of Haemophilus influenzae Hin47 protein has a decreased protease activity which is less than about 10% of that of natural Hin47 protein and preferably substantially the same immunogenic properties as natural Hin47 protein. An isolated an purified nucleic a |
| 6025342 |
Analog of Haemophilus Hin47 with reduced protease activity |
February 15, 2000 |
| An isolated and purified analog of Haemophilus influenza Hin47 protein has a decreased protease activity which is less than about 10% of that of natural Hin47 protein and preferably substantially the same immunogenic properties as natural Hin47 protein. An isolated and purified nucleic a |
| 6020183 |
Analog of haemophilus Hin47 with reduced protease activity |
February 1, 2000 |
| An isolated and purified analog of Haemophilus influenzae Hin47 protein has a decreased protease activity which is less than about 10% of that of natural Hin47 protein and preferably substantially the same immunogenic properties as natural Hin47 protein. An isolated an purified nucleic a |
| 6020182 |
Subunit respiratory syncytial virus vaccine preparation |
February 1, 2000 |
| The fusion (F) protein, attachment (G) protein and matrix (M) protein of respiratory syncytial virus (RSV) are isolated and purified from respiratory syncytial virus by mild detergent extraction of the proteins from concentrated virus, loading the protein onto a hydroxyapatite or oth |
| 6018022 |
Modification of pertussis toxin |
January 25, 2000 |
| The three-dimensional structure of crystalline pertussis holotoxin (PT) has been determined by X-ray crystallography. Crystal structures have also been determined for complexes of pertussis toxin with molecules relevant to the biological activity of PT. These three-dimensional structures |
| 5981503 |
Analog of Haemophilus Hin47 with reduced protease activity |
November 9, 1999 |
| An isolated and purified analog of Haemophilus influenzae Hin47 protein has a decreased protease activity which is less than about 10 % of that of natural Hin47 protein and preferably substantially the same immunogenic properties as natural Hin47 protein. An isolated an purified nucleic |
| 5977304 |
Modification of pertussis toxin |
November 2, 1999 |
| The three-dimensional structure of crystalline pertussis holotoxin (PT) has been determined by X-ray crystallography. Crystal structures have also been determined for complexes of pertussis toxin with molecules relevant to the biological activity of PT. These three-dimensional structures |
| 5965385 |
Modification of pertussis toxin |
October 12, 1999 |
| The three-dimensional structure of crystalline pertussis holotoxin (PT) has been determined by X-ray crystallography. Crystal structures have also been determined for complexes of pertussis toxin with molecules relevant to the biological activity of PT. These three-dimensional structures |
| 5962430 |
Analog of Haemophilus Hin47 with reduced protease activity |
October 5, 1999 |
| An isolated and purified analog of Haemophilus influenzae Hin47 protein has a decreased protease activity which is less than about 10% of that of natural Hin47 protein and preferably substantially the same immunogenic properties as natural Hin47 protein. An isolated an purified nucleic a |
| 5939297 |
Analog of haemophilus HIN47 with reduced protease activity |
August 17, 1999 |
| An isolated and purified analog of Haemophilus influenzae Hin47 protein has a decreased protease activity which is less than about 10% of that of natural Hin47 protein and preferably substantially the same immunogenic properties as natural Hin47 protein. An isolated an purified nucleic a |
| 5935573 |
Method of use of an analog of Haemophilus influenzae Hin47 with reduced protease activity |
August 10, 1999 |
| An isolated and purified analog of Haemophilus influenzae Hin47 protein has a decreased protease activity which is less than about 10% of that of natural Hin47 protein and preferably substantially the same immunogenic properties as natural Hin47 protein. An isolated an purified nucleic a |
| 5869302 |
Analog of haemophilus hin47 with reduced protease activity |
February 9, 1999 |
| An isolated and purified analog of Haemophilus influenzae Hin47 protein has a decreased protease activity which is less than about 10% of that of natural Hin47 protein and preferably substantially the same immunogenic properties as natural Hin47 protein. An isolated an purified nucleic a |
| 5856122 |
Modification of pertussis toxin |
January 5, 1999 |
| The three-dimensional structure of crystalline pertussis holotoxin (PT) has been determined by X-ray crystallography. Crystal structures have also been determined for complexes of pertussis toxin with molecules relevant to the biological activity of PT. These three-dimensional structures |
| 5665353 |
Composition containing an analog of haemophilus Hin47 with reduced protease activity |
September 9, 1997 |
| An isolated and purified analog of Haemophilus influenzae Hin47 protein has a decreased protease activity which is less than about 10% of that of natural Hin47 protein and preferably substantially the same immunogenic properties as natural Hin47 protein. An isolated an purified nucleic a |
| 5656436 |
Analog of Haemophilus Hin47 with reduced protease activity |
August 12, 1997 |
| An isolated and purified analog of Haemophilus influenzae Hin47 protein has a decreased protease activity which is less than about 10% of that of natural Hin47 protein and preferably substantially the same immunogenic properties as natural Hin47 protein. An isolated an purified nucleic a |
| 5506139 |
Analog of haemophilus Hin47 with reduced protease activity |
April 9, 1996 |
| An isolated and purified analog of Haemophilus influenzae Hin47 protein has a decreased protease activity which is less than about 10% of that of natural Hin47 protein and preferably substantially the same immunogenic properties as natural Hin47 protein. An isolated an purified nucleic a |
